AstraZeneca’s immunotherapy Imfinzi already has an FDA approval for inoperable lung cancer patients who’ve responded to chemo and radiation—and that’s something none of its rivals will be able to say for a while. Friday, it hit another key benchmark to
read moreAre you carrying out work on behalf of charities?Would you like to do more in this area?If the answer is yes, tell the industry by entering the new, Charity Challenge today. More: Try a different challenge and make it count!
read moreThe PharmaTimes Marketer of the Year Awards will return to London in November, alongside Communications Team of the Year and the all-new Sales Awards. Get involved with the 25th anniversary celebrations as this unique competition continues to raise standards, drive innovation
read moreIf not, you should. Now!Dr Jim Golby PhD FCIPD, co-chair of the competition’s executive steering group (ESG) says: “I strongly believe that the newly imagined 2018 Pharma Sales Awards will provide a superb methodology for identifying and recognising the very
read moreWith MERS and Lassa fever projects already funded, the Coalition for Epidemic Preparedness Innovations is ready to put a check mark beside the third disease on its priority list. The outbreak-focused alliance is granting up to $25 million to two
read moreAdding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin’s lymphoma. More: Genmab/Novatis’ Arzerra fails to hit NHL targets Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals